The Trump administration has decided against implementing a proposal for Medicare and Medicaid to cover weight loss drugs, the Centers for Medicare and Medicaid Services said in a filing published Friday by the agency. A CMS spokesperson said the agency now believes that finalizing the proposal "is not appropriate at this time.
Main Idea: The Trump administration decided not to move forward with a plan to let Medicare and Medicaid cover weight loss drugs.
Key Points:
Many patients with obesity may have to pay out of pocket for weight loss drugs, and some people may delay treatment.
Taxpayers and state Medicaid programs may avoid billions in added costs.
Rate how each entity in this article affected the American people.
No entity suggestions or linked entities saved yet.
His administration made the coverage decision, making him a central political figure in the story.
Oversees CMS and is part of the policy context around the decision.
Named top federal health official whose oversight of CMS is relevant to the policy shift.
Named adviser and special government employee quoted criticizing the Biden-era proposal.
Cited for cost estimates that helped frame the debate over expanding coverage.
Named drug mentioned as another example of a medication Medicare already covers in some cases.
Named drug mentioned as an example of a medication Medicare already covers in some cases.
Comments here are the same thread shown when this article appears in The Pulse.
No comments on this article yet.
Sign in to commentPlatform where Calley Means posted the quoted criticism.